Nicotine Addiction and Other Psychiatric Disorders

Psychiatric TimesPsychiatric Times Vol 18 No 2
Volume 18
Issue 2

Smoking is not only a comorbid condition for schizophrenia; it may also have an effect on other psychiatric conditions.

Smoking is not only a comorbid condition for schizophrenia (see "Nicotine Addiction and Schizophrenia" in the February issue ofPsychiatric Times pg39-Ed.); it may also have an effect on other psychiatric conditions.

Major Depression

In patients with major depression, smoking prevalence rates are 50% to 70% (Figure) (George and Krystal, 2000; Hughes et al., 1986). Glassman et al. (1988) found that 61% of smokers presenting to a smoking cessation program had a past history of major depression. Anda et al. (1990) found that 39% of individuals with a moderate degree of depressive symptoms were smokers. Smokers with depressive symptoms have a much harder time quitting and require more attempts to quit (Glassman, 1993; Glassman et al., 1990). Smoking cessation is also associated with negative affective states (Hall et al., 1993). In patients with a history of major depression, smoking cessation may lead to re-emergence of major depressive symptoms (Covey et al., 1997; Glassman et al., 1990), although a recent study has questioned this phenomenon (Tsoh et al., 2000). Furthermore, open-label nicotine patch administration rapidly improves depressive symptoms in non-smokers with major depression (Salin-Pascual et al., 1996).

Nonetheless, there are few controlled studies of pharmacological treatments for nicotine dependence in patients with major depression (Covey et al., 2000), although behavioral treatments such as cognitive-behavioral therapy are promising (Hall et al., 1994).Bipolar Disorder

Hughes et al. (1986) reported smoking-prevalence rates of 70% in bipolar outpatients, while Gonzalez-Pinto et al. (1998) reported that 63% of Spanish patients with bipolar disorder had lifetime histories of smoking and that 51% were current smokers. Glassman and colleagues (1993) found that bipolar patients were at risk for depressive recurrence during smoking cessation.

Panic Disorder

Smoking has been found to be a risk factor for the onset of panic disorder. Amering et al. (1999) found that smoking rates were elevated (56%) in patients with panic disorder as compared to controls. A study by Pohl et al. (1992) also found higher rates of current smoking among such patients than among controls. Breslau and Klein (1999) found that smoking can lead to panic attacks, but the reverse relationship was not supported. Furthermore, smoking cessation reduced the risk of panic attacks. Amering et al. (1999), however, found that individuals who quit smoking reported little reduction in panic symptoms. A recent study (Johnson et al., 2000) found that heavy smoking (>1 pack/day) in adolescence, controlling for confounding variables such as age, educational status and parental smoking, was associated with a higher risk of panic disorder, generalized anxiety disorder and agoraphobia. Thus, the relationship between smoking and panic attacks requires further study using prospective designs.

Posttraumatic Stress Disorder

Beckham et al. (1995) found that the smoking rate in posttraumatic stress disorder (PTSD) patients was 60% and that women with PTSD had higher rates of smoking than controls (Acierno et al., 1996). Beckham et al. (1997) also found that combat veterans with PTSD had higher rates of smoking (53%) than controls (45%). PTSD veterans reported higher rates of heavy smoking (>25 cigs/day) than non-PTSD veterans (48% versus 28%). In heavy smokers, there were more total PTSD symptoms and Cluster C (avoidance and numbing) and Cluster D (hyper-arousal) symptoms.

Neuropsychiatric Disorders

There is increasing evidence that nicotine can reduce neurological impairment associated with Parkinson's disease (PD), Alzheimer's disease (AD) and Tourette's syndrome (TS) (Piasecki and Newhouse, 2000). In PD, this may relate to stimulation of nicotinic acetylcholine receptors (nAChRs) on nigrostriatal dopamine (DA) neurons and stimulation of nAChRs on subcortical cholinergic neurons in AD. Subcortical nAChRs are reduced in both PD and AD (Piasecki and Newhouse, 2000).

The incidence of both PD and AD is lower in smokers than in non-smokers (Lee, 1994; Morens et al., 1995), suggesting that nicotine may have neuroprotective effects. Nicotine administration in rats improves cognitive tasks related to working memory function (Levin and Simon, 1998) and attention and concentration in non-smoking controls and in patients with Alzheimer's disease (Newhouse et al., 1988). Nicotine gum and patch can reduce tic severity and potentiate therapeutic effects of neuroleptics in TS (Shytle et al., 1996).

Cognitive-enhancing effects of nicotine are difficult to interpret in smokers, since nicotine may simply be reversing tobacco abstinence, which itself may impair cognitive function. Thus, further studies of nicotine effects on mood and cognition are needed, in both smokers and non-smokers.

Substance Abuse Disorders

While a discussion of the association between nicotine addiction and other substance abuse disorders is beyond the scope of this article, there are high rates of cigarette smoking in patients with alcohol, cocaine and opioid dependence (Bobo et al., 1995). Nicotine may act as a conditioned cue for alcohol and illicit substance use, and the nAChR antagonist mecamylamine may reduce cocaine cue-reactivity (Reid et al., 1999). Thus, attempts to treat nicotine dependence in psychiatric patients must involve treatment of the non-nicotine substance abuse disorder.




Acierno RA, Kilpatrick DG, Resnick HS et al. (1996), Violent assault, posttraumatic stress disorder, and depression. Risk factors for cigarette use among adult women. Behav Modif 20(4):363-384.


Amering M, Bankier B, Berger P et al. (1999), Panic disorder and cigarette smoking behavior. Compr Psychiatry 40(1):35-38.


Anda RF, Williamson DF, Escobedo LG et al. (1990), Depression and the dynamics of smoking. A national perspective. JAMA 264(12):1541-1545 [see comment].


Beckham JC, Kirby AC, Feldman ME et al. (1997), Prevalence and correlates of heavy smoking in Vietnam veterans with chronic posttraumatic stress disorder. Addict Behav 22(5):637-647.


Beckham JC, Roodman AA, Shipley RH et al. (1995), Smoking in Vietnam combat veterans with post-traumatic stress disorder. J Trauma Stress 8(3):461-472.


Bobo JK, Slade J, Hoffman AL (1995), Nicotine addiction counseling for chemical dependent patients. Psychiatr Serv 46(9):945-947.


Breslau N, Klein DF (1999), Smoking and panic attacks: an epidemiologic investigation. Arch Gen Psychiatry 56(12):1141-1147.


Covey LS, Glassman AH, Stetner F, Rivelli S (2000), A trial of sertraline for smokers with past major depression. Presented at the Society for Research on Nicotine and Tobacco Sixth Annual Meeting. Arlington, Va.: Feb. 18-20.


Covey LS, Glassman AH, Stetner F (1997), Major depression following smoking cessation. Am J Psychiatry 154(2):263-265.


George TP, Krystal JH (2000), Comorbidity of psychiatric and substance abuse disorders. Current Opinion in Psychiatry 13(3):327-331.


Glassman AH (1993), Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150(4):546-553 [see comment].


Glassman AH, Covey LS, Dalack GW et al. (1993), Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 54(6):670-679.


Glassman AH, Helzer JE, Covey LS et al. (1990), Smoking, smoking cessation, and major depression. JAMA 264(12):1546-1549 [see comment].


Glassman AH, Stetner F, Walsh BT et al. (1988), Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 259(19):2863-2866.


Gonzalez-Pinto A, Gutierrez M, Ezcurra J et al. (1998), Tobacco smoking and bipolar disorder. J Clin Psychiatry 59(5):225-228.


Hall SM, Munoz RF, Reus VI (1994), Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol 62(1):141-146.


Hall SM, Munoz RF, Reus VI, Sees KL (1993), Nicotine, negative affect, and depression. J Consult Clin Psychol 61(5):761-767.


Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA (1986), Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143(8):993-997.


Johnson JG, Cohen P, Pine DS et al. (2000), Association between cigarette smoking and anxiety disorders during adolescence and early adulthood. JAMA 284(18):2348-2351.


Lee PN (1994), Smoking and Alzheimer's disease: a review of epidemiological evidence. Neuroepidemiology 13(4):133-144.


Levin ED, Simon BB (1998), Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 138(3-4):217-230.


Morens DM, Grandinetti A, Reed D et al. (1995), Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45(6):1041-1051.


Newhouse PA, Sunderland T, Tariot PN et al. (1988), Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl) 95(2):171-175.


Piasecki M, Newhouse PA (2000), Nicotine in Psychiatry: Psychopathology and Emerging Therapeutics. Washington, D.C.: American Psychiatric Press Inc.


Pohl R, Yeragani VK, Balon R et al. (1992), Smoking in patients with panic disorder. Psychiatry Res 43(3):253-262.


Reid MS, Mickalian JD, Delucchi KL, Berger SP (1999), A nicotinic antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects. Neuropsychopharmacology 20(3):297-307.


Salin-Pascual RJ, Rosas M, Jimenez-Genchi A et al. (1996), Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry 57(9):387-389.


Shytle RD, Silver AA, Philipp MK et al. (1996), Transdermal nicotine for Tourette's syndrome. Drug Development Research 38(3-4):290-298.


Tsoh JY, Humfleet GL, Munoz RF et al. (2000), Development of major depression after treatment for smoking cessation. Am J Psychiatry 157(3):368-374.

Related Videos
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
brain depression
nicotine use
brain schizophrenia
© 2024 MJH Life Sciences

All rights reserved.